Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Allogeneic stem cell transplantation in HIV-1 infected patients with high-risk hematological disorders

Kwon, Mia,b,*; Bailén, Rebecaa,b,*; Balsalobre, Pascuala,b,g; Jurado, Manuelc; Bermudez, Aranchad; Badiola, Jonc; Esquirol, Alberte; Miralles, Pilarf,b; López-Fernández, Elisac; Sanz, Jaimeg; Yanez, Lucreciad; Colorado, Mercedesd; Piñana, José Luisg; Dorado, Nievesa,b; Solán, Lauraa,b; Laperche, Carolina Martíneza,b; Anguita, Javiera,b; Serrano, Davida,b; Díez-Martin, José Luisa,b,h on behalf of Grupo Español de Trasplante Hematopoyético y Terapia Celular (GETH)

doi: 10.1097/QAD.0000000000002209

Introduction: Although a number of patients with HIV infection and hematological disease have successfully undergone allogeneic hematopoietic stem cell transplantation (HSCT), short and long-term outcomes remain not well known. We report the largest Spanish experience treating HIV-infected adult patients with high-risk hematological malignancies with allogeneic HSCT.

Methods: We retrospectively reviewed 22 HIV-positive patients who received allogeneic HSCT in 5 centers in Spain.

Results: 22 patients with high-risk hematological malignancies were transplanted between 1999 and 2018. Median age was 44 years. With a median follow-up of 65 months (8–112), OS and EFS were 46%. NRM was 14% at 12 months and relapse was 24% at 24 months. Grade II-IV aGvHD rate was 40%, and moderate/severe cGvHD rate was 41% at 24 months. All patients received cART. Two patients showed severe toxicity related to drug interaction with anti-retroviral therapy. 68% of patients showed infectious complications with viral infections as the most frequent cause. Two patients had invasive aspergillosis and one patient presented disseminated tuberculosis. All survivors except one maintained undetectable HIV load at last follow-up after HSCT.

Conclusions: Allogeneic HSCT is an effective therapy for high-risk hematological malignancies in patients with HIV infection, and long-term HIV suppression with cART is feasible. However, drug interactions with anti-retroviral agents, occurrence of GVHD, and frequent infectious complications account for a complex procedure in this population. Selected HIV-infected patients with hematologic malignancies should be considered for allo-HSCT when indicated, in experienced centers.

aDepartment of Hematology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

bGregorio Marañón Health Research Institute, Madrid, Spain

cDepartment of Hematology, Hospital Universitario Virgen de las Nieves, Granada, Spain

dDepartment of Hematology, Hospital Marqués de Valdecilla, Santander, Spain

eDepartment of Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

fDepartment of Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain

gDepartment of Hematology, Hospital Universitario y Politécnico de la Fe, Valencia, Spain

hUniversidad Complutense de Madrid, Madrid, Spain.

*Equal contribution

Correspondence to Mi Kwon, MD, Department of Hematology, Hospital G. Univ. Gregorio Marañon, Doctor Esquerdo 46, 28007, Madrid, Spain. Tel: +34 915868443; fax: +34 915868394; e-mail:

Received 28 July, 2018

Revised 23 December, 2018

Accepted 15 January, 2019

Copyright © 2019 Wolters Kluwer Health, Inc.